Off-Label Medical Device Cases That Ended Differently: Acquittals, Pleas and Dismissed Charges

Whistleblower Justice Network

Vascular Solutions won a medical device off-label acquittal for itself and its chief executive over a vein-treatment kit. A jury acquitted Acclarent’s executives of felony charges but convicted them of misdemeanor medical device offenses. Stryker Biotech resolved its case with a corporate misdemeanor while prosecutors dropped the employee charges. Norian and Synthes entered plea agreements. For a medical device insider, the useful comparison is what each case tested: the product’s intended use, the sales program and, in the civil cases, the treatment charged to the government.

The person designing the product may know why a particular fluid works in it. The sales representative may know what physicians were taught to do with it. Someone handling reimbursement may know what the practice was told it could bill. These cases show how those different parts of the business can meet in the same investigation.

What the Manufacturer, Physician and Payer Each Do

Promotion evidence and billing evidence can sit in different businesses: the manufacturer sells the medical device, while the hospital or practice bills for the treatment.

For implants, the physician often strongly influences the brand and type selected. The hospital buys the product and generally receives a bundled Medicare payment for the procedure or stay. Under consignment arrangements, the manufacturer may retain ownership until use. The operation can therefore trigger the manufacturer’s sale and the hospital’s claim.

The representative also brings practical knowledge into the room. A Senate Finance Committee staff report describes representatives ordering, delivering and stocking medical devices, handling instrumentation and assisting surgeons. Sales instructions can travel with the person who helps make the product available for the procedure. In the cases below, that practical channel carried demonstrations, training and even instructions for mixing products together.

What Is the FDA Definition of Off-Label Use?

Off-label use means using a medical device outside the labeling cleared or approved by the Food and Drug Administration. The physician’s treatment decision, the manufacturer’s intended use and the payer’s coverage decision each have their own evidence.

Food and Drug Administration clearance generally compares a medical device with an existing medical device and its intended use. Premarket approval requires evidence providing reasonable assurance of safety and effectiveness for the labeled conditions. Medicare coverage and payment are separate decisions. In Acclarent, the practical question was particularly concrete: the company obtained clearance for a saline spacer and sold a product designed around a steroid.

Vascular Solutions and the Jury’s Acquittal

A jury acquitted Vascular Solutions and its chief executive on all five counts on February 26, 2016. The prosecution concerned the Vari-Lase Short Kit and its promotion for sealing perforator veins, which connect superficial veins to deeper veins in the leg.

The kit’s Food and Drug Administration clearance covered treatment of superficial veins in the leg. The criminal indictment charged that the company promoted the kit for perforator veins while describing the intended use as short vein segments. According to the indictment, the company’s own design file counted perforator veins as short vein segments.

The criminal case included misdemeanor medical device charges and a felony conspiracy charge. The government took its account of the sales program to trial and lost.

The company had separately agreed to a $520,000 civil settlement in July 2014. The Justice Department alleged that Vascular Solutions promoted the Short Kit for perforator-vein treatment after failing to obtain Food and Drug Administration clearance for that use and after its clinical trial missed safety and effectiveness benchmarks. The government alleged that the promotion caused physicians and other purchasers to submit claims for services federal healthcare programs would not reimburse. A former sales representative brought the whistleblower case.

The whistleblower’s complaint also alleged that sales advice reached the timing of treatment:

Further, Vascular representatives have been instructed to recommend that physicians treat a patient’s individual veins on separate days so as to be reimbursed at the highest rate possible, as the HCPCS reimbursement rate for additional veins is lower than the rate for the first vein treated on a given day.

United States ex rel. Bui v. Vascular Solutions, Inc., whistleblower’s complaint

That allegation concerns how the company allegedly encouraged a practice to schedule billable treatment. It gives a reimbursement employee something specific to recognize alongside the promotional materials. The civil case concerned the government bills the promotion allegedly caused. Vascular Solutions settled those claims before the criminal jury acquitted it of the medical device and conspiracy charges.

Acclarent and the Product Behind the Sales Pitch

Acclarent’s former chief executive and former sales vice president were convicted of ten misdemeanor medical device counts in 2016. The jury rejected the conspiracy and remaining wire-fraud charges and found no intent to defraud or mislead on the medical device counts. The medical device convictions rested on distribution without the required authorization for the steroid use.

The First Circuit’s account of the criminal trial describes the Relieva Stratus as a small perforated balloon attached to a catheter. Acclarent obtained clearance in 2006 to use it with saline as a spacer maintaining a sinus opening after surgery. Its development project, however, had been built around delivering the steroid Kenalog to the ethmoid sinuses.

The pore size tells the story. The company calibrated the openings so that the thicker steroid would seep out gradually. Saline ran out rapidly. The product’s physical design pointed to the same use that its sales strategy promoted.

Acclarent asked the Food and Drug Administration to add a therapeutic-agent indication in 2007. The agency told the company that the change required a new submission and clearance before marketing for that use. Acclarent never completed an approved study supporting steroid delivery and never submitted the required premarket notification for that intended use.

The trial evidence also showed how the company brought physicians toward the steroid use. Sales trainees learned to ask leading questions that would prompt surgeons to inquire about drug delivery. A physician discussion guide described Kenalog as the agent that worked optimally with Stratus while offering no explanation of a clinical benefit from saline delivery.

At a professional conference, the company divided its booth between U.S. and international representatives. The U.S. representatives directed questions about the product’s uses to the international side, where representatives discussed Kenalog delivery. Elsewhere, a demonstration showed saline immediately running out of the balloon while explaining why the thicker drug escaped slowly. The sales channel and the engineering pointed in the same direction.

Acclarent’s corporate civil resolution addressed the payment consequences. In July 2016, the company agreed to pay $18 million to resolve allegations that its marketing and distribution of Stratus for drug delivery caused providers to submit false claims to Medicare and other federal health care programs. The government alleged that employees trained physicians with a steroid-delivery video and used a milky substance resembling Kenalog in demonstrations. Patients received the treatment, and taxpayers faced the bill.

Stryker Biotech and the Dismissed Charges

Stryker Biotech’s corporate misdemeanor resolution came with dismissal of the felony charges and all charges against its then-current and former employees, according to Stryker Corporation’s annual securities filing. The prosecution ended through that resolution, rather than a jury’s acquittal.

The criminal indictment had alleged that the company promoted mixing OP-1 products with Calstrux, a bone void filler. It alleged that sales instructions supplied recipes to surgeons, medical technicians and others. Some called for molding the mixture into elongated shapes described as cigars, tootsie rolls or vienna sausages. The alleged promotion reached the preparation of the material used in surgery.

OP-1 Implant and OP-1 Putty had entered the market under a humanitarian device exemption. The restrictions described in the indictment limited treatment to a condition affecting fewer than 4,000 patients in the United States and prohibited selling the medical devices for profit. The government also charged false statements about the number of patients treated with OP-1 Putty, connecting the company’s reporting to the restriction on its market.

For someone in the business, the relevant records include the mixing instructions, product training and patient-use reporting.

Norian and the Proposed Test Market

Norian and Synthes entered corporate plea agreements in a case involving bone cement promoted for vertebral compression fractures. The criminal case concerned Norian XR and Norian SRS, and the FDA-cleared XR label expressly warned against the spinal use being promoted.

The criminal information charged that the company chose a limited test market in place of seeking authorization for the intended use and conducting approved clinical testing. The alleged plan was to judge safety and effectiveness by the company’s own standards, get to market ahead of competitors and generate published studies that could persuade other surgeons to use the product in the spine.

That makes the proposed literature part of the sales story. According to the information, the company wanted the test market to produce the studies that would support wider use. An employee involved in clinical development could recognize the connection between the commercial launch plan and the evidence the company wanted to publish.

The criminal information also alleged that pilot work had already shown clotting when the cement contacted human blood and cement-related clots lodging in a pig’s lungs. It charged that the company proceeded with the marketing program despite that knowledge.

The Justice Department also reported misdemeanor guilty pleas by executives responsible for the business.

The separate civil agreement required Synthes to pay $138,000. It covered allegations that false safety and effectiveness representations caused government claims or purchases for spinal procedures involving 31 beneficiaries of Medicare, TRICARE and veterans’ health programs. The government alleged that the use was not reasonable and necessary. Here the civil claim connected the sales representations to specific government-funded procedures.

What Connects Promotion to a False Claim?

The civil cases connect the manufacturer’s conduct to a treatment decision and a request for government money. Vascular Solutions’ settlement concerned allegedly nonreimbursable vein treatment. Acclarent’s concerned allegedly induced claims for use of Stratus as a drug-delivery medical device. Norian’s agreement identified the government beneficiaries whose procedures were at issue.

A 2020 forensic accounting analysis published in the Journal of Forensic and Investigative Accounting places the request for payment at the center of False Claims Act analysis. It also distinguishes what was false from what the participants knew. Applied to these medical device cases, that means following the promotion into the procedure and the claim, with the internal decisions beside it.

Therakos supplies a further example of that connection across a change of ownership. The Justice Department alleged that the company promoted its drug and medical device systems for unapproved pediatric uses and caused false claims to Medicaid, the Federal Employee Health Benefits Program and TRICARE. In its November 2020 announcement, a Johnson & Johnson subsidiary agreed to pay $10 million over the earlier conduct, and The Gores Group agreed to pay $1.5 million over allegations that the practices continued after its acquisition. The alleged sales program continued across the ownership change, and the civil resolution addressed both periods.

The insider’s contribution is knowing how those connections worked inside the business: why the medical device was designed that way, what the sales force was instructed to say, and what providers were encouraged to bill. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Training Shows the Intended Use

If you recognize a medical device sold for one purpose while the training, design or reimbursement advice points to another, bring that account to our medical device whistleblower experts. We assess the commercial decisions and government-payment connection with you, build the case strategy and bring in medical device whistleblower lawyers who understand manufacturer promotion and provider billing. We stay beside you as your whistleblower experts from the first conversation through the case.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365